Inresa Arzneimittel GmbH is a pharmaceutical manufacturer whose core business is direct supply of hospitals in Germany with generic, prescription medicines for the anaesthesia, emergency and intensive care specialties. In addition, the company distributes this assortment to pharmaceutical wholesalers and pharmacies domestically and abroad. Inresa is a 100% subsidiary of Flynn Pharma (Holdings) Ltd., Stevenage (United Kingdom), and manages business development and procurement for the entire European market in a matrix organisation while quality and sales processes are controlled nationally. Key financials for the reporting year include a gross profit of EUR 5,690,263.69, a net income of EUR 746,829.94 and cash equivalents of approx. EUR 4.4 million with no bank liabilities.
Alle Maßnahmen zur Zulassung von Arzneimitteln sowie Handel und Vertrieb auf allen Stufen. Arzneimittel in diesem Sinne sind solche nach § 2 Abs.l, § 2 Abs.2, § 2 Abs.3 und § 2 Abs.4 Arzneimittelgesetz. Die Gesellschaft kann weiter mit Chemikalien oder sämtlichen Produkten aus dem Bereich der Medizintechnik handeln oder diese vertreiben.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 4556 (as of 3 November 2026)
| Name | Type | City |
|---|---|---|
| David Fakes | Geschäftsführer(in) | Herts AL& OPP (Großbritannien) |
| Henric Wassmer | Geschäftsführer(in) | Wittnau |
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 4556 (as of 3 November 2026)
| Date | Contract | Value |
|---|---|---|
| 20.3.2025 | Supplier · Bundesamt für Ausrüstung, Informationstechnik und Nutzung der Bundeswehr | — |
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2025 | Rohergebnis€6.3M2 | €413,575 | €14,027,766 | 23 |
| 2024 | Rohergebnis€5.7M2 | €748,463 | €12,276,929 | 20 |
| 2023 | Rohergebnis€6.2M2 | €1,124,129 | €14,962,604 | 21 |
| 2022 | €17,368,889 | €1,874,894 | €13,963,834 | 23 |
| 2021 | €16,651,994 | €1,746,067 | €12,163,534 | 21 |
| 2020 | Rohergebnis€5.4M2 | €936,426 | €10,230,517 | 16 |
| 2019 | — | — | €8,485,347 | 15 |
| 2018 | — | — | €7,018,614 | 21 |
| 2017 | — | — | €5,824,066 | 24 |
| 2016 | — | — | €6,403,787 | 18 |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
2 Rohergebnis nach § 276 HGB: Umsatzerlöse abzüglich Materialaufwand bzw. Herstellungskosten. Kleine und mittelgroße Kapitalgesellschaften dürfen diese Posten zusammenfassen; die Umsatzerlöse selbst sind dann nicht veröffentlicht und liegen über dem Rohergebnis.
Sign in to download data
Source: German Commercial Register (Handelsregister) Freiburg Local Court, HRB 4556 (as of 3 November 2026)
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €1,620,428 | 69.7% |
| Depreciation | €704,059 | 30.3% |
